Krystal Biotech Inc (KRYS) - Net Assets
Based on the latest financial reports, Krystal Biotech Inc (KRYS) has net assets worth $1.28 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.40 Billion) and total liabilities ($120.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Krystal Biotech Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.28 Billion |
| % of Total Assets | 91.39% |
| Annual Growth Rate | 152.84% |
| 5-Year Change | 105.46% |
| 10-Year Change | N/A |
| Growth Volatility | 5331.33 |
Krystal Biotech Inc - Net Assets Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's net assets have evolved over time, based on quarterly financial data. See KRYS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Krystal Biotech Inc (2016–2025)
The table below shows the annual net assets of Krystal Biotech Inc from 2016 to 2025. For live valuation and market cap data, see how much is Krystal Biotech Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.22 Billion | +28.87% |
| 2024-12-31 | $946.38 Million | +21.54% |
| 2023-12-31 | $778.64 Million | +49.10% |
| 2022-12-31 | $522.23 Million | -12.02% |
| 2021-12-31 | $593.58 Million | +103.22% |
| 2020-12-31 | $292.08 Million | +43.94% |
| 2019-12-31 | $202.91 Million | +79.21% |
| 2018-12-31 | $113.23 Million | +128.86% |
| 2017-12-31 | $49.47 Million | +17019.03% |
| 2016-12-31 | $289.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Krystal Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2531300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $24.16 Million | 1.98% |
| Other Comprehensive Income | $1.14 Million | 0.09% |
| Other Components | $1.19 Billion | 97.93% |
| Total Equity | $1.22 Billion | 100.00% |
Krystal Biotech Inc Competitors by Market Cap
The table below lists competitors of Krystal Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
$9.23 Billion |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
$9.23 Billion |
|
Joby Aviation
NYSE:JOBY
|
$9.24 Billion |
|
The Siam Cement Public Company Limited
BK:SCC
|
$9.24 Billion |
|
Bangkok Dusit Medical Services Public Company Limited
BK:BDMS
|
$9.21 Billion |
|
U-Haul Holding Company
NYSE:UHAL-B
|
$9.21 Billion |
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
$9.19 Billion |
|
Doosan
KO:000150
|
$9.19 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Krystal Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 946,380,000 to 1,219,560,000, a change of 273,180,000 (28.9%).
- Net income of 204,831,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 1,326,000.
- Other factors increased equity by 67,023,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $204.83 Million | +16.8% |
| Other Comprehensive Income | $1.33 Million | +0.11% |
| Other Changes | $67.02 Million | +5.5% |
| Total Change | $- | 28.87% |
Book Value vs Market Value Analysis
This analysis compares Krystal Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5054.51x to 8.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.07 | $341.66 | x |
| 2017-12-31 | $9.23 | $341.66 | x |
| 2018-12-31 | $10.11 | $341.66 | x |
| 2019-12-31 | $12.76 | $341.66 | x |
| 2020-12-31 | $15.55 | $341.66 | x |
| 2021-12-31 | $26.74 | $341.66 | x |
| 2022-12-31 | $20.49 | $341.66 | x |
| 2023-12-31 | $28.06 | $341.66 | x |
| 2024-12-31 | $31.82 | $341.66 | x |
| 2025-12-31 | $40.72 | $341.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Krystal Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.80%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 52.64%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.09x
- Recent ROE (16.80%) is above the historical average (-45.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -397.92% | 0.00% | 0.00x | 7.55x | $-1.18 Million |
| 2017 | -16.01% | 0.00% | 0.00x | 1.01x | $-12.87 Million |
| 2018 | -9.62% | -1060.27% | 0.01x | 1.03x | $-22.21 Million |
| 2019 | -9.41% | 0.00% | 0.00x | 1.03x | $-39.38 Million |
| 2020 | -11.01% | 0.00% | 0.00x | 1.06x | $-61.38 Million |
| 2021 | -11.72% | 0.00% | 0.00x | 1.06x | $-128.93 Million |
| 2022 | -26.80% | 0.00% | 0.00x | 1.07x | $-192.20 Million |
| 2023 | 1.40% | 21.56% | 0.06x | 1.05x | $-66.93 Million |
| 2024 | 9.42% | 30.69% | 0.28x | 1.12x | $-5.48 Million |
| 2025 | 16.80% | 52.64% | 0.29x | 1.09x | $82.88 Million |
Industry Comparison
This section compares Krystal Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Krystal Biotech Inc (KRYS) | $1.28 Billion | -397.92% | 0.09x | $9.22 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more